Equities

SAGE Therapeutics Inc

SAGE Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.06
  • Today's Change0.21 / 4.33%
  • Shares traded109.10k
  • 1 Year change-73.96%
  • Beta0.8651
Data delayed at least 15 minutes, as of Nov 22 2024 15:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

  • Revenue in USD (TTM)106.40m
  • Net income in USD-337.59m
  • Incorporated2010
  • Employees487.00
  • Location
    SAGE Therapeutics Inc215 1st StCAMBRIDGE 02142-1213United StatesUSA
  • Phone+1 (617) 299-8380
  • Fax+1 (617) 299-8379
  • Websitehttps://www.sagerx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lexicon Pharmaceuticals Inc5.23m-216.39m278.96m285.00--1.56--53.35-0.7513-0.75130.0180.49380.01750.69553.2518,347.37-72.42-24.41-81.77-29.0193.5498.49-4,138.33-84.927.43-12.320.3588--766.19-54.71-73.74--37.68--
Tevogen Bio Holdings Inc0.0057.92m279.86m17.004.36------0.37580.37580.00-0.04520.00----0.001,217.57-----------------702.58--------99.69------
Rezolute Inc0.00-69.31m281.60m59.00--2.37-----1.27-1.270.002.050.00----0.00-58.64-50.36-62.66-53.25------------0.00-------32.19------
C4 Therapeutics Inc33.67m-105.50m283.06m145.00--1.17--8.41-1.70-1.700.52173.440.095--6.21232,193.10-29.76-25.91-33.20-29.45-----313.35-292.35----0.00---33.251.40-3.37---8.68--
Aldeyra Therapeutics Inc0.00-44.80m286.43m10.00--3.37-----0.7538-0.75380.001.430.00----0.00-33.86-36.79-39.67-40.77------------0.1522------39.47------
Vanda Pharmaceuticals Inc.190.86m-16.39m288.04m203.00--0.5322--1.51-0.2824-0.28243.299.280.29679.305.30940,187.20-2.556.61-2.957.6293.6290.55-8.5915.184.84--0.000.00-24.27-0.0496-60.02-36.96-56.77--
Absci Corp4.21m-97.67m289.57m155.00--1.45--68.83-0.9357-0.93570.04021.760.0178--3.6627,141.94-41.42---46.85-------2,321.56-----157.350.0269---0.5046---5.40------
Voyager Therapeutics Inc163.78m25.88m296.12m162.009.240.89669.571.810.58760.58762.946.060.4545--14.291,011,012.007.180.63788.420.8203----15.801.30----0.000.00511.16101.01385.14---5.43--
SAGE Therapeutics Inc106.40m-337.59m296.69m487.00--0.5376--2.79-5.58-5.581.769.020.1354--5.24218,478.40-42.95-21.88-48.97-23.3091.7599.63-317.29-131.50----0.00--1,024.84-0.8606-1.63---28.01--
iTeos Therapeutics Inc35.00m-121.25m296.92m157.00--0.4701--8.48-3.15-3.150.906417.290.05--1.43222,929.90-17.315.84-18.167.02-----346.4422.09----0.000.00-95.29---216.54--68.45--
Nautilus Biotechnology Inc0.00-70.21m298.84m161.00--1.34-----0.561-0.5610.001.780.00----0.00-24.29---25.05--------------0.00-------9.93------
Compass Pathways PLC (ADR)0.00-144.32m304.47m186.00--1.58-----2.19-2.190.002.820.00----0.00-52.83-40.85-57.18-44.48------------0.1337-------29.46---12.68--
Aclaris Therapeutics Inc27.08m-37.00m308.58m91.00--2.37--11.40-0.5198-0.51980.38061.820.1352--78.61297,582.40-18.47-47.29-20.87-53.8753.5344.00-136.65-549.18----0.00--5.0338.41-1.81---0.703--
Kodiak Sciences Inc0.00-191.62m310.43m108.00--1.67-----3.65-3.650.003.520.00----0.00-41.64-31.73-46.43-33.61------------0.00------21.97--134.76--
Design Therapeutics Inc0.00-47.78m315.38m54.00--1.25-----0.8465-0.84650.004.460.00----0.00-17.02---17.64--------------0.00-------5.61------
Data as of Nov 22 2024. Currency figures normalised to SAGE Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

54.06%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20245.68m9.28%
RTW Investments LPas of 30 Sep 20245.59m9.14%
Fidelity Management & Research Co. LLCas of 30 Sep 20245.27m8.62%
Bellevue Asset Management AGas of 30 Sep 20244.46m7.29%
BlackRock Fund Advisorsas of 30 Sep 20244.13m6.76%
SSgA Funds Management, Inc.as of 30 Sep 20242.93m4.78%
Millennium Management LLCas of 30 Sep 20241.50m2.45%
Jacobs Levy Equity Management, Inc.as of 30 Sep 20241.26m2.06%
Geode Capital Management LLCas of 30 Sep 20241.24m2.03%
Palo Alto Investors LPas of 30 Sep 20241.01m1.65%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.